Crage Medical Co., Limited

Carsgen Therapeutics Co., Ltd.

Shanghai United Imaging Healthcare Co., Ltd.

Carsgen Therapeutics Limited

Cafa Therapeutics Limited

Shanghai Cancer Institute

Bo Song

Huamao Wang

Xiumei Cai

Peng Wang

Zonghai Li

Mingchao Wang

Hongxia Zhao

Yusheng Yin

Zhimin Shi

Zeyan Pan

Yuanmei Chen

Yinyu Zhu

The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

Antibody against glypican-3 and application thereof

Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof

Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.

GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof

The present disclosure provides a display apparatus. The display apparatus may include a display panel including a frame area and a display area; a display component configured to display a content including a target portion and a background portion on the display area; an image acquisition device configured to acquire an image of the display panel, wherein the image includes a representation of at least one portion of the frame area and at least one portion of the display area; and a control device configured to control the display component to adjust the background portion of the content displayed on the display area according to the image of the display panel.

Systems, methods, and apparatuses for display

Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.

Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent

The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.

Tumor-specific anti-EGFR antibody and application thereof

The present invention provides fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin.

Growing community of inventors

Shanghai, China

Bo Song